Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
Manasanch EE et al. Leuk Lymphoma. 2014 Sep 27:1-24. [Epub ahead of print].
Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A et al. Appl Immunohistochem Mol Morphol. 2014 Sep 26. [Epub ahead of print].
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G et al. Ann Hematol. 2014 Sep 18. [Epub ahead of print].
Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques.
Biran N et al. Curr Hematol Malig Rep. 2014 Sep 16. [Epub ahead of print].
Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
Hao M et al. Int J Cancer. 2014 Sep 15. doi: 10.1002/ijc.29199. [Epub ahead of print].
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.
Isoda A et al. Cancer Sci. 2014 Sep 13. doi: 10.1111/cas.12529. [Epub ahead of print].
18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F et al. Clin Exp Med. 2014 Sep 14. [Epub ahead of print].
Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma.
Qu X et al. Med Oncol. 2014 Oct;31(10):219. doi: 10.1007/s12032-014-0219-x. Epub 2014 Sep 13.
Neuroimaging of plasmacytoma. A pictorial review.
Agarwal A. Neuroradiol J. 2014 Sep;27(4):431-7. doi: 10.15274/NRJ-2014-10078. Epub 2014 Aug 29.
Oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.
Fujisawa M et al. Cancer Sci. 2014 Sep 2. doi: 10.1111/cas.12527. [Epub ahead of print].
Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent m-protein studies in serum and urine.
Behdad A et al. Am J Clin Pathol. 2014 Sep;142(3):398-410. doi: 10.1309/AJCPO5GQPXF8QCEC.
Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE et al. Ann Hematol. 2014 Sep 26. [Epub ahead of print].